Skip to main content

Zai Lab Limited (ZLAB)

NASDAQ: ZLAB · IEX Real-Time Price · USD
100.75 1.03 (1.03%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap9.63B
Revenue (ttm)86.78M
Net Income (ttm)-536.52M
Shares Out95.41M
EPS (ttm)-6.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume398,941
Open100.29
Previous Close99.72
Day's Range98.77 - 101.50
52-Week Range80.46 - 193.54
Beta1.24
AnalystsStrong Buy
Price Target120.83 (+19.9%)
Est. Earnings DateNov 8, 2021

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and...

IndustryBiotechnology
IPO DateSep 20, 2017
Employees1,194
Stock ExchangeNASDAQ
Ticker SymbolZLAB
Full Company Profile

Financial Performance

In 2020, Zai Lab's revenue was $48.96 million, an increase of 277.04% compared to the previous year's $12.99 million. Losses were -$268.91 million, 37.8% more than in 2019.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for Zai Lab stock is "Strong Buy." The 12-month stock price forecast is 120.83, which is an increase of 19.93% from the latest price.

Price Target
$120.83
(19.93% upside)
Analyst Consensus: Strong Buy

News

Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial

Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). ZL-1102 is an investigati...

2 days ago - Benzinga

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that Zai Lab ...

2 days ago - Business Wire

ZL-1102, Zai Lab's Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psori...

Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque psoriasi...

3 days ago - GlobeNewsWire

Zai Lab Appoints Scott Morrison to its Board of Directors

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical com...

5 days ago - GlobeNewsWire

Zai Lab Announces Upcoming Presentations in October Investor Conferences

SHANGHAI and SAN FRANCISCO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that manag...

1 week ago - GlobeNewsWire

Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greate...

-- Demonstrated efficacy and safety consistent with global SOPHIA study-- Company expects to file BLA in China in advanced HER2+ breast cancer by approximately year end 2021

2 weeks ago - GlobeNewsWire

Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Pa...

SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company deve...

2 weeks ago - GlobeNewsWire

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy...

Final data collection is expected in the first half of 2022

2 weeks ago - GlobeNewsWire

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy...

ST. HELIER, Jersey & SHANGHAI--(BUSINESS WIRE)-- #GastricCancer--Novocure and Zai Lab announced that the last patient has been enrolled in a phase 2 pilot trial of TTFields plus chemotherapy in gastric ...

Other symbols:NVCR
2 weeks ago - Business Wire

Zai Lab Holds Virtual Research and Development Day

-- Expects to have more than 15 marketed products in more than 35 indications by 2025-- Aspires to become a leading global biopharmaceutical company

1 month ago - GlobeNewsWire

Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community

SHANGHAI and SAN FRANCISCO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that it will expand i...

1 month ago - GlobeNewsWire

Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China

Potential first-in-class therapy for a subset of gastric and gastroesophageal (GEJ) cancers that overexpress fibroblast growth factor receptor 2 (FGFR2b) Potential first-in-class therapy for a subset of...

1 month ago - GlobeNewsWire

Zai Lab Announces Upcoming Presentations in September Investor Conferences

SHANGHAI and SAN FRANCISCO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that manag...

1 month ago - GlobeNewsWire

Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates

Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT

2 months ago - GlobeNewsWire

The Vanguard Health Care Fund's Top 5 Trades of the 2nd Quarter

The Vanguard Health Care Fund (Trades, Portfolio) has revealed its portfolio for the second quarter of this year. Major trades for the fund include a reduction in its portfolio-leading UnitedHealth Grou...

Other symbols:PPDSYKUNH
2 months ago - GuruFocus

Schrödinger, Zai Lab Team Up For Cancer Program Targeting DNA Damage Response

Schrödinger Inc (NASDAQ: SDGR) and Zai Lab Limited (NASDAQ: ZLAB) have collaborated to discover, develop, and commercialize oncology candidate targeting DNA damage response. The research program will be...

2 months ago - Benzinga

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

Agreement provides Schrödinger and Zai Lab with pipeline expansion opportunities in precision oncology Agreement provides Schrödinger and Zai Lab with pipeline expansion opportunities in precision oncology

2 months ago - GlobeNewsWire

Zai Lab to Announce Second Quarter 2021 Financial Results

SHANGHAI and SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will report fi...

3 months ago - GlobeNewsWire

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Other symbols:BEAMBOLTGMABMGNX
3 months ago - PennyStocks

MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal

MacroGenics Inc (NASDAQ: MGNX) and Zai Lab Limited (NASDAQ: ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules. The first collaborati...

Other symbols:MGNX
4 months ago - Benzinga

Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific ...

SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASDAQ...

4 months ago - GlobeNewsWire

3 Stocks With Solid Balance Sheets for the Value Investor

Benjamin Graham, the father of value investing, suggested screening the market for stocks that have a current ratio of more than 2 plus more working capital than long-term debt.

Other symbols:TECH
4 months ago - GuruFocus

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688...

Other symbols:MRTX
4 months ago - PRNewsWire

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first pati...

4 months ago - GlobeNewsWire

Zai Lab Announces Upcoming Presentations in June Investor Conferences

SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that manage...

4 months ago - GlobeNewsWire